TSHA
Taysha Gene Therapies, Inc.
Price Chart
Latest Quote
$6.19
+0.34 (+5.81%)
Current Price
| Previous Close | $5.85 |
| Open | $5.90 |
| Day High | $6.37 |
| Day Low | $5.90 |
| Volume | 2,273,671 |
Stock Information
| Shares Outstanding | 287.36M |
| Total Debt | $68.55M |
| Cash Equivalents | $276.58M |
| Revenue | $7.47M |
| Net Income | $-129.88M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.78B |
| EPS (TTM) | $-0.38 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.47B |
| Sales | $7.47M |
| Income | $-129.88M |
| Book/sh | $0.74 |
| Cash/sh | $0.96 |
| Employees | 99 |
Financial Ratios
| Quick Ratio | 13.76 |
| Current Ratio | 14.04 |
| Debt/Eq | 32.34 |
Returns & Margins
| ROA | -37.77% |
| ROE | -97.28% |
| Gross Margin | 100.00% |
| Operating Margin | -1774.37% |
Ownership
| Insider Ownership | 10.65% |
| Institutional Ownership | 95.75% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -13.99 |
| P/S | 238.09 |
| P/B | 8.39 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $12.23 |
Technical Indicators
| SMA20 | $5.69 |
| SMA50 | $5.92 |
| SMA200 | $4.87 |
| RSI | 55.38 |
| ATR | 0.3967 |
| Shares Float | 196.74M |
| Short Float | 12.76% |
| Short Ratio | 15.27 |
| Volatility | 1.18 |
| Rel Volume | 0.96 |
Performance History
| Week | +14.63% |
| Month | +13.68% |
| Quarter | +39.10% |
| 6 Months | +7.47% |
| YTD | +17.90% |
| Year | +141.80% |
| 3 Years | +650.30% |
| 5 Years | -74.84% |
| 10 Years | -74.27% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $6.19 | 2,274,400 |
| 2026-06-16 | $5.85 | 1,653,800 |
| 2026-06-15 | $5.97 | 5,629,700 |
| 2026-06-12 | $5.71 | 2,048,600 |
| 2026-06-11 | $5.58 | 1,545,200 |
| 2026-06-10 | $5.40 | 2,180,800 |
| 2026-06-09 | $5.36 | 4,310,600 |
| 2026-06-08 | $5.43 | 3,501,700 |
| 2026-06-05 | $5.50 | 1,360,700 |
| 2026-06-04 | $5.89 | 2,600,900 |
| 2026-06-03 | $5.55 | 1,653,500 |
| 2026-06-02 | $5.69 | 1,550,400 |
| 2026-06-01 | $5.97 | 1,561,200 |
| 2026-05-29 | $5.87 | 2,155,600 |
| 2026-05-28 | $5.92 | 2,100,800 |
| 2026-05-27 | $5.75 | 1,559,800 |
| 2026-05-26 | $5.59 | 2,728,800 |
| 2026-05-22 | $5.49 | 1,656,200 |
| 2026-05-21 | $5.54 | 2,208,800 |
| 2026-05-20 | $5.49 | 3,137,500 |
| 2026-05-19 | $5.18 | 2,308,500 |
| 2026-05-18 | $5.45 | 2,293,200 |
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
đ° Latest News
Taysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year Recovery
Simply Wall St. âĸ 2026-06-13T12:12:45Z
Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-06-11T18:00:15Z
Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026
Insider Monkey âĸ 2026-05-14T16:51:52Z
Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights
Insider Monkey âĸ 2026-05-11T21:21:47Z
Assessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent Volatility
Simply Wall St. âĸ 2026-05-09T22:16:55Z
Taysha Gene Therapies, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-07T12:30:00Z
Taysha Gene Therapies Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-07T07:24:28Z
Has Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?
Simply Wall St. âĸ 2026-04-28T06:06:14Z
Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago Levels
Insider Monkey âĸ 2026-04-22T14:25:54Z
This is Why Taysha Gene Therapies, Inc. (TSHA) is one of the Best Healthcare Penny Stocks to Buy
Insider Monkey âĸ 2026-04-14T09:50:44Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $9,773,000 | $8,333,000 | $15,451,000 | $2,502,000 |
| Operating Revenue | $9,773,000 | $8,333,000 | $15,451,000 | $2,502,000 |
| Expenses | ||||
| Interest Expense | $63,000 | $102,000 | $4,998,000 | $3,798,000 |
| Total Expenses | $120,271,000 | $94,954,000 | $86,825,000 | $128,529,000 |
| Other Income Expense | $-7,658,000 | $-9,515,000 | $-38,766,000 | $-36,438,000 |
| Other Non Operating Income Expenses | $-6,459,000 | $-4,693,000 | $-1,585,000 | $-18,000 |
| Net Non Operating Interest Income Expense | $9,161,000 | $6,838,000 | $-1,426,000 | $-3,549,000 |
| Interest Expense Non Operating | $63,000 | $102,000 | $4,998,000 | $3,798,000 |
| Operating Expense | $120,271,000 | $94,954,000 | $86,825,000 | $128,529,000 |
| General And Administrative Expense | $33,868,000 | $28,953,000 | $30,047,000 | $37,360,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-108,995,000 | $-89,298,000 | $-111,566,000 | $-166,014,000 |
| Net Interest Income | $9,161,000 | $6,838,000 | $-1,426,000 | $-3,549,000 |
| Interest Income | $9,224,000 | $6,940,000 | $3,572,000 | $249,000 |
| Normalized Income | $-107,796,000 | $-84,476,000 | $-74,385,000 | $-129,594,000 |
| Net Income From Continuing And Discontinued Operation | $-108,995,000 | $-89,298,000 | $-111,566,000 | $-166,014,000 |
| Total Operating Income As Reported | $-110,498,000 | $-91,459,000 | $-72,439,000 | $-162,447,000 |
| Net Income Common Stockholders | $-108,995,000 | $-89,298,000 | $-111,566,000 | $-166,014,000 |
| Net Income | $-108,995,000 | $-89,298,000 | $-111,566,000 | $-166,014,000 |
| Net Income Including Noncontrolling Interests | $-108,995,000 | $-89,298,000 | $-111,566,000 | $-166,014,000 |
| Net Income Continuous Operations | $-108,995,000 | $-89,298,000 | $-111,566,000 | $-166,014,000 |
| Pretax Income | $-108,995,000 | $-89,298,000 | $-111,566,000 | $-166,014,000 |
| Special Income Charges | $0 | $-4,838,000 | $-2,463,000 | $-36,420,000 |
| Interest Income Non Operating | $9,224,000 | $6,940,000 | $3,572,000 | $249,000 |
| Operating Income | $-110,498,000 | $-86,621,000 | $-71,374,000 | $-126,027,000 |
| Per Share | ||||
| Diluted EPS | $-0.34 | $-0.36 | $-0.96 | $-3.78 |
| Basic EPS | $-0.34 | $-0.36 | $-0.96 | $-3.78 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-106,588,000 | $-83,129,000 | $-68,016,000 | $-124,624,000 |
| Total Unusual Items | $-1,199,000 | $-4,822,000 | $-37,181,000 | $-36,420,000 |
| Total Unusual Items Excluding Goodwill | $-1,199,000 | $-4,822,000 | $-37,181,000 | $-36,420,000 |
| Reconciled Depreciation | $1,145,000 | $1,245,000 | $1,371,000 | $1,172,000 |
| EBITDA (Bullshit earnings) | $-107,787,000 | $-87,951,000 | $-105,197,000 | $-161,044,000 |
| EBIT | $-108,932,000 | $-89,196,000 | $-106,568,000 | $-162,216,000 |
| Diluted Average Shares | $319,711,972 | $250,134,421 | $116,121,482 | $43,952,015 |
| Basic Average Shares | $319,711,972 | $250,134,421 | $116,121,482 | $43,952,015 |
| Diluted NI Availto Com Stockholders | $-108,995,000 | $-89,298,000 | $-111,566,000 | $-166,014,000 |
| Impairment Of Capital Assets | $0 | $4,838,000 | $1,065,000 | $36,420,000 |
| Gain On Sale Of Security | $-1,199,000 | $16,000 | $-34,718,000 | - |
| Research And Development | $86,403,000 | $66,001,000 | $56,778,000 | $91,169,000 |
| Selling General And Administration | $33,868,000 | $28,953,000 | $30,047,000 | $37,360,000 |
| Other Gand A | $33,868,000 | $28,953,000 | $30,047,000 | $37,360,000 |
| Other Special Charges | - | - | $1,398,000 | - |
Fetched: 2026-06-13
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $246,938,000 | $71,525,000 | $74,937,000 | $949,000 |
| Total Assets | $343,320,000 | $160,364,000 | $172,731,000 | $126,276,000 |
| Total Non Current Assets | $18,673,000 | $18,234,000 | $22,863,000 | $29,859,000 |
| Other Non Current Assets | $2,498,000 | $2,368,000 | $2,455,000 | $3,953,000 |
| Current Assets | $324,647,000 | $142,130,000 | $149,868,000 | $96,417,000 |
| Other Current Assets | $802,000 | $308,000 | $292,000 | $466,000 |
| Current Deferred Assets | $195,000 | $135,000 | $681,000 | $724,000 |
| Restricted Cash | $449,000 | $449,000 | $449,000 | $0 |
| Prepaid Assets | $3,434,000 | $2,202,000 | $2,506,000 | $7,347,000 |
| Cash Cash Equivalents And Short Term Investments | $319,767,000 | $139,036,000 | $143,940,000 | $87,880,000 |
| Cash And Cash Equivalents | $319,767,000 | $139,036,000 | $143,940,000 | $87,880,000 |
| Assets Held For Sale Current | - | $0 | $2,000,000 | $0 |
| Cash Equivalents | - | $138,308,000 | $142,425,000 | - |
| Cash Financial | - | $728,000 | $1,515,000 | $87,880,000 |
| Non Current Deferred Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $70,143,000 | $63,180,000 | $61,107,000 | $59,928,000 |
| Long Term Debt And Capital Lease Obligation | $68,278,000 | $61,303,000 | $59,461,000 | $58,407,000 |
| Long Term Debt | $50,106,000 | $43,942,000 | $40,508,000 | $37,967,000 |
| Current Debt And Capital Lease Obligation | $1,865,000 | $1,877,000 | $1,646,000 | $1,521,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $96,382,000 | $88,839,000 | $97,794,000 | $125,327,000 |
| Total Non Current Liabilities Net Minority Interest | $69,830,000 | $62,612,000 | $61,038,000 | $62,537,000 |
| Other Non Current Liabilities | $1,552,000 | $1,309,000 | $1,577,000 | $4,130,000 |
| Current Liabilities | $26,552,000 | $26,227,000 | $36,756,000 | $62,790,000 |
| Other Current Liabilities | $777,000 | $1,190,000 | $1,177,000 | $650,000 |
| Current Deferred Liabilities | $0 | $9,773,000 | $18,106,000 | $33,557,000 |
| Payables And Accrued Expenses | $14,485,000 | $8,145,000 | $12,014,000 | $23,080,000 |
| Payables | $6,275,000 | $3,592,000 | $6,366,000 | $10,946,000 |
| Accounts Payable | $6,275,000 | $3,592,000 | $6,366,000 | $10,946,000 |
| Equity | ||||
| Common Stock Equity | $246,938,000 | $71,525,000 | $74,937,000 | $949,000 |
| Total Equity Gross Minority Interest | $246,938,000 | $71,525,000 | $74,937,000 | $949,000 |
| Stockholders Equity | $246,938,000 | $71,525,000 | $74,937,000 | $949,000 |
| Gains Losses Not Affecting Retained Earnings | $-192,000 | $-4,031,000 | $0 | - |
| Other Equity Adjustments | $-192,000 | $-4,031,000 | - | - |
| Retained Earnings | $-711,300,000 | $-602,305,000 | $-513,007,000 | $-401,441,000 |
| Other | ||||
| Ordinary Shares Number | $285,051,648 | $204,943,306 | $186,960,193 | $63,207,507 |
| Share Issued | $285,051,648 | $204,943,306 | $186,960,193 | $63,207,507 |
| Tangible Book Value | $246,938,000 | $71,525,000 | $74,937,000 | $949,000 |
| Invested Capital | $297,044,000 | $115,467,000 | $115,445,000 | $38,916,000 |
| Working Capital | $298,095,000 | $115,903,000 | $113,112,000 | $33,627,000 |
| Capital Lease Obligations | $20,037,000 | $19,238,000 | $20,599,000 | $21,961,000 |
| Total Capitalization | $297,044,000 | $115,467,000 | $115,445,000 | $38,916,000 |
| Additional Paid In Capital | $958,427,000 | $677,859,000 | $587,942,000 | $402,389,000 |
| Capital Stock | $3,000 | $2,000 | $2,000 | $1,000 |
| Common Stock | $3,000 | $2,000 | $2,000 | $1,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $18,172,000 | $17,361,000 | $18,953,000 | $20,440,000 |
| Current Deferred Revenue | $0 | $9,773,000 | $18,106,000 | $33,557,000 |
| Current Capital Lease Obligation | $1,865,000 | $1,877,000 | $1,646,000 | $1,521,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $9,425,000 | $5,242,000 | $3,813,000 | $3,982,000 |
| Current Accrued Expenses | $8,210,000 | $4,553,000 | $5,648,000 | $12,134,000 |
| Net PPE | $16,175,000 | $15,866,000 | $20,408,000 | $25,906,000 |
| Accumulated Depreciation | $-4,684,000 | $-3,584,000 | $-2,979,000 | $-1,642,000 |
| Gross PPE | $20,859,000 | $19,450,000 | $23,387,000 | $27,548,000 |
| Leases | $2,152,000 | $2,117,000 | $2,117,000 | $2,091,000 |
| Construction In Progress | $4,292,000 | $4,251,000 | $6,823,000 | $9,633,000 |
| Other Properties | $12,745,000 | $11,511,000 | $12,450,000 | $13,811,000 |
| Machinery Furniture Equipment | $1,670,000 | $1,571,000 | $1,997,000 | $2,013,000 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-13
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-93,828,000 | $-81,599,000 | $-80,387,000 | $-113,259,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-93,090,000 | $-81,225,000 | $-73,018,000 | $-88,390,000 |
| Cash Flow From Continuing Operating Activities | $-93,090,000 | $-81,225,000 | $-73,018,000 | $-88,390,000 |
| Operating Gains Losses | $1,199,000 | $-16,000 | $36,951,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-738,000 | $-374,000 | $-7,369,000 | $-24,869,000 |
| Investing Cash Flow | $-604,000 | $-363,000 | $-7,352,000 | $-24,930,000 |
| Cash Flow From Continuing Investing Activities | $-604,000 | $-363,000 | $-7,352,000 | $-24,930,000 |
| Net Other Investing Changes | $134,000 | $11,000 | $17,000 | $-61,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $264,306,000 | $76,780,000 | $140,790,000 | $53,244,000 |
| Financing Cash Flow | $274,589,000 | $76,684,000 | $136,393,000 | $52,097,000 |
| Cash Flow From Continuing Financing Activities | $274,589,000 | $76,684,000 | $136,393,000 | $52,097,000 |
| Net Other Financing Charges | $-337,000 | $-185,000 | $-1,015,000 | $-1,400,000 |
| Net Common Stock Issuance | $264,306,000 | $76,780,000 | $140,790,000 | $53,244,000 |
| Common Stock Issuance | $264,306,000 | $76,780,000 | $140,790,000 | $53,244,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-40,612,000 | $0 | $-43,000,000 | $0 |
| Issuance Of Debt | $49,853,000 | $0 | $39,550,000 | $0 |
| Interest Paid Supplemental Data | $5,399,000 | $5,282,000 | $4,952,000 | $2,775,000 |
| End Cash Position | $322,531,000 | $141,636,000 | $146,540,000 | $90,517,000 |
| Beginning Cash Position | $141,636,000 | $146,540,000 | $90,517,000 | $151,740,000 |
| Changes In Cash | $180,895,000 | $-4,904,000 | $56,023,000 | $-61,223,000 |
| Proceeds From Stock Option Exercised | $1,379,000 | $89,000 | $68,000 | $253,000 |
| Net Issuance Payments Of Debt | $9,241,000 | $0 | $-3,450,000 | $0 |
| Net Long Term Debt Issuance | $9,241,000 | $0 | $-3,450,000 | $0 |
| Long Term Debt Payments | $-40,612,000 | $0 | $-43,000,000 | $0 |
| Long Term Debt Issuance | $49,853,000 | $0 | $39,550,000 | $0 |
| Net PPE Purchase And Sale | $-738,000 | $-374,000 | $-3,869,000 | $-20,619,000 |
| Purchase Of PPE | $-738,000 | $-374,000 | $-3,869,000 | $-20,619,000 |
| Change In Working Capital | $-5,371,000 | $-12,467,000 | $-18,012,000 | $18,518,000 |
| Change In Other Working Capital | $-9,773,000 | $-8,333,000 | $-15,451,000 | $33,557,000 |
| Change In Payables And Accrued Expense | $6,136,000 | $-4,341,000 | $-8,572,000 | $-17,127,000 |
| Change In Accrued Expense | $6,289,000 | $-1,421,000 | $-6,277,000 | $-9,323,000 |
| Change In Payable | $-153,000 | $-2,920,000 | $-2,295,000 | $-7,804,000 |
| Change In Account Payable | $-153,000 | $-2,920,000 | $-2,295,000 | $-7,804,000 |
| Change In Prepaid Assets | $-1,734,000 | $207,000 | $6,011,000 | $2,088,000 |
| Other Non Cash Items | $5,634,000 | $1,370,000 | $9,268,000 | $3,471,000 |
| Stock Based Compensation | $13,298,000 | $13,103,000 | $7,905,000 | $18,043,000 |
| Asset Impairment Charge | $0 | $4,838,000 | $1,065,000 | $36,420,000 |
| Depreciation Amortization Depletion | $1,145,000 | $1,245,000 | $1,371,000 | $1,172,000 |
| Depreciation And Amortization | $1,145,000 | $1,245,000 | $1,371,000 | $1,172,000 |
| Depreciation | $1,145,000 | $1,245,000 | $1,371,000 | $1,172,000 |
| Gain Loss On Investment Securities | $1,199,000 | $-16,000 | $35,585,000 | - |
| Net Income From Continuing Operations | $-108,995,000 | $-89,298,000 | $-111,566,000 | $-166,014,000 |
| Net Intangibles Purchase And Sale | - | $0 | $-3,500,000 | $-4,250,000 |
| Purchase Of Intangibles | - | $0 | $-3,500,000 | $-4,250,000 |
Fetched: 2026-06-13